TNF Superfamily and ILC2 Activation in Asthma
Open Access
- 29 February 2024
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 14 (3) , 294
Abstract
Eosinophilic asthma is the most prevalent and well-defined phenotype of asthma. Despite a majority of patients responding to corticosteroid therapy and T2 biologics, there remains a subset that have recurrent asthma exacerbations, highlighting a need for additional therapies to fully ameliorate airway eosinophilia. Group 2 innate lymphoid cells (ILC2) are considered key players in the pathogenesis of eosinophilic asthma through the production of copious amounts of type 2 cytokines, namely IL-5 and IL-13. ILC2 numbers are increased in the airways of asthmatics and with the greatest numbers of activated ILC2 detected in sputa from severe prednisone-dependent asthma with uncontrolled eosinophilia. Although epithelial-derived cytokines are important mediators of ILC2 activation, emerging evidence suggests that additional pathways stimulate ILC2 function. The tumor necrosis factor super family (TNFSF) and its receptors (TNFRSF) promote ILC2 activity. In this review, we discuss evidence supporting a relationship between ILC2 and TNFSF/TNFRSF axis in eosinophilic asthma and the role of this relationship in severe asthma with airway autoimmune responses.Keywords
Funding Information
- Canadian Lung Association/Ontario Thoracic Society
This publication has 108 references indexed in Scilit:
- IL-33-ILC2 axis promotes anti-tumor CD8+ T cell responses via OX40 signalingBiochemical and Biophysical Research Communications, 2022
- Osteoprotegerin mediate RANK/RANKL signaling inhibition eases asthma inflammatory reaction by affecting the survival and function of dendritic cellsAllergologia et Immunopathologia, 2019
- Group 2 innate lymphoid cells are elevated and activated in chronic rhinosinusitis with nasal polypsImmunity, Inflammation and Disease, 2017
- Increased serum APRIL differentially correlates with distinct cytokine profiles and disease activity in systemic lupus erythematosus patientsRheumatology International, 2014
- Tumor necrosis factorCancer Letters, 2013
- Altered expression of TNFSF4 and TRAF2 mRNAs in peripheral blood mononuclear cells in patients with systemic lupus erythematosus: association with atherosclerotic symptoms and lupus nephritisInflammation Research, 2012
- RANK, RANKL and osteoprotegerin in bone biology and diseaseCurrent Reviews in Musculoskeletal Medicine, 2009
- Clinical significance of IL-18, IL-15, IL-12 and TNF-α measurement in rheumatoid arthritisClinical Rheumatology, 2005
- B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: Longitudinal observationsArthritis & Rheumatism, 2003
- The coexpression of CD45RA and CD45RO isoforms on T cells during the S/G2/M stages of cell cycleCellular Immunology, 1991